Our goodwill impairment testing is performed annually during the fourth quarter of each fiscal year in addition to periods where changes in circumstances indicate that the carrying value of our goodwill assets may not be recoverable. No impairment charges were recognized during the three and nine months ended September 29, 2024. We did identify indicators of a potential impairment as of June 30, 2024 related to our Interventional Urology North America reporting unit, included within our Americas operating segment. The indicators of a potential impairment primarily arose from lower than anticipated sales results from our UroLift product line (“UroLift”), primarily driven by the adverse impact of persistent end-market challenges within the U.S. office site of service. We performed a quantitative impairment test of the reporting unit using both the income and the market approaches, which determined that the fair value of the reporting unit exceeded the carrying value. The more significant judgments and assumptions in determining the fair value included the amount and timing of expected future cash flows, the expected long-term growth rates and the discount rate used to estimate the present value of the future cash flows. Our assessment indicates that the Interventional Urology North America reporting unit is susceptible to future impairment charges if future revenue is lower than our current expectations, in particular with respect to the adverse impacts stemming from end market conditions related to UroLift, as well as from continuing negative impacts from macroeconomic factors, including increased inflation and higher interest rates. The carrying value of goodwill allocated to the Interventional Urology North America reporting unit as of September 29, 2024 was $643.9 million.


	Gross Carrying Amount				Accumulated Amortization
	September 29, 2024		December 31, 2023		September 29, 2024		December 31, 2023
Customer relationships	$	1,362,046	$	1,363,839	$	(610,061)	$	(561,753)
In-process research and development	23,666		27,476		—		—
Intellectual property	1,872,243		1,890,957		(834,835)		(745,094)
Distribution rights	23,360		23,301		(22,687)		(22,048)
Trade names	607,163		610,146		(95,790)		(84,864)
Non-compete agreements	21,930		21,934		(21,930)		(21,934)
	$	3,910,408	$	3,937,653	$	(1,585,303)	$	(1,435,693)